Isaac E. Marx

Woomera Therapeutics — United States

Medicine · Health Sciences

11h-index423citations21works5.02yr avg
OpenAlex↗ORCID↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Alzheimer's disease research and treatments(4), Chronic Lymphocytic Leukemia Research(4), Phenothiazines and Benzothiazines Synthesis and Activities(3), Protein Structure and Dynamics(2), Drug Transport and Resistance Mechanisms(2)

Publications21 total

Targeted degradation of MK2 is insufficient to block inflammatory cytokine production in human cells due to cooperativity with MK3 and MK5
Frontiers in Immunology·2026Open Access
54020 Potent and selective TYK2 degraders, devoid of JAK activity, potently and completely suppress IL12/23 and IFN-a signaling pathways.
Journal of the American Academy of Dermatology·2024Open Access
Discovery and Preclinical Characterization of BIIB129, a Covalent, Selective, and Brain-Penetrant BTK Inhibitor for the Treatment of Multiple Sclerosis
Journal of Medicinal Chemistry·2024· 15 citedOpen Access
Discovery of Phospholipase D Inhibitors with Improved Drug-like Properties and Central Nervous System Penetrance
ACS Medicinal Chemistry Letters·2022· 12 citedOpen Access
Discovery and Preclinical Characterization of BIIB091, a Reversible, Selective BTK Inhibitor for the Treatment of Multiple Sclerosis
Journal of Medicinal Chemistry·2021· 37 citedOpen Access
Utilizing structure based drug design and metabolic soft spot identification to optimize the in vitro potency and in vivo pharmacokinetic properties leading to the discovery of novel reversible Bruton’s tyrosine kinase inhibitors
Bioorganic & Medicinal Chemistry·2021· 11 citedOpen Access
Next‐generation Bruton's tyrosine kinase inhibitor BIIB091 selectively and potently inhibits B cell and Fc receptor signaling and downstream functions in B cells and myeloid cells
Clinical & Translational Immunology·2021· 24 citedOpen Access
CCDC 1947050: Experimental Crystal Structure Determination
The Cambridge Structural Database·2019Open Access
Utilization of Cyclic Amides as Masked Aldehyde Equivalents in Reductive Amination Reactions
The Journal of Organic Chemistry·2019· 8 cited
The discovery of benzoxazine sulfonamide inhibitors of NaV1.7: Tools that bridge efficacy and target engagement
Bioorganic & Medicinal Chemistry Letters·2017· 20 citedOpen Access
Sulfonamides as Selective Na<sub>V</sub>1.7 Inhibitors: Optimizing Potency, Pharmacokinetics, and Metabolic Properties to Obtain Atropisomeric Quinolinone (AM-0466) that Affords Robust in Vivo Activity
Journal of Medicinal Chemistry·2017· 66 citedOpen Access
Sulfonamides as Selective Na<sub>V</sub>1.7 Inhibitors: Optimizing Potency and Pharmacokinetics While Mitigating Metabolic Liabilities
Journal of Medicinal Chemistry·2017· 49 citedOpen Access
Correction to “Sulfonamides as Selective Na<sub>V</sub>1.7 Inhibitors: Optimizing Potency and Pharmacokinetics to Enable <i>in Vivo</i> Target Engagement”
ACS Medicinal Chemistry Letters·2017
Sulfonamides as Selective Na<sub>V</sub>1.7 Inhibitors: Optimizing Potency and Pharmacokinetics to Enable in Vivo Target Engagement
ACS Medicinal Chemistry Letters·2016· 37 citedOpen Access
Development of 2-aminooxazoline 3-azaxanthenes as orally efficacious β-secretase inhibitors for the potential treatment of Alzheimer’s disease
Bioorganic & Medicinal Chemistry Letters·2015· 29 citedOpen Access
Lead Optimization and Modulation of hERG Activity in a Series of Aminooxazoline Xanthene β-Site Amyloid Precursor Protein Cleaving Enzyme (BACE1) Inhibitors
Journal of Medicinal Chemistry·2014· 40 citedOpen Access
Inhibitors of β-Site Amyloid Precursor Protein Cleaving Enzyme (BACE1): Identification of (<i>S</i>)-7-(2-Fluoropyridin-3-yl)-3-((3-methyloxetan-3-yl)ethynyl)-5′<i>H</i>-spiro[chromeno[2,3-<i>b</i>]pyridine-5,4′-oxazol]-2′-amine (AMG-8718)
Journal of Medicinal Chemistry·2014· 61 citedOpen Access
S35972, a direct‐acting thrombin inhibitor with high oral bioavailability and antithrombotic efficacy
Journal of Thrombosis and Haemostasis·2011· 4 citedOpen Access
Exploring the Depletion Layer: An Investigation into How Water Reacts when Confined to a Hydrophobic Surface
Bulletin of the American Physical Society·2011
Discovery of α-amidosulfones as potent and selective agonists of CB2: Synthesis, SAR, and pharmacokinetic properties
Bioorganic & Medicinal Chemistry Letters·2008· 10 citedOpen Access
page 1 of 2Next →

Frequent Co-authors

Robert T. Fremeau(10), Matthew M. Weiss(10), Thomas A. Dineen(9), Charles R. Kreiman(8), Erin F. DiMauro(7), Emily A. Peterson(7), Margaret Y. Chu‐Moyer(6), Hakan Günaydin(6), Liyue Huang(6), Thomas Kornecook(6), Daniel S. La(6), Joseph Ligutti(6), Min-Hwa Jasmine Lin(6), Violeta Yu(6), Bryan D. Moyer(6), Brian T. Hopkins(6), R. Foti(5), Hua Gao(5), Hanh Nho Nguyen(5), Russell F. Graceffa(4)